GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma
Abstract Background Cancer stem cells (CSCs) are implicated in carcinogenesis, cancer progression, and recurrence. Several biomarkers have been described for pancreatic ductal adenocarcinoma (PDAC) CSCs; however, their function and mechanism remain unclear. Method In this study, secretome analysis w...
Guardado en:
Autores principales: | Jung Hyun Jo, Sun A Kim, Jeong Hoon Lee, Yu Rang Park, Chanyang Kim, Soo Been Park, Dawoon E. Jung, Hee Seung Lee, Moon Jae Chung, Si Young Song |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eb3af251a62c4c54b9cc1856215d522c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma
por: Ricki T. Krog, et al.
Publicado: (2021) -
Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
por: Kostas Palamaris, et al.
Publicado: (2021) -
TPH1 and 5-HT<sub>7</sub> Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma
por: Prakash Chaudhary, et al.
Publicado: (2021) -
Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma
por: Sachie Kiryu, et al.
Publicado: (2021) -
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug
por: Emilia Alors-Perez, et al.
Publicado: (2021)